Clinical Trial Update: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita [Phase 3]

View source ↗

Summary

A multicenter Phase 3 randomized, double-blind, vehicle-controlled trial evaluating QTORIN 3.9% Rapamycin Anhydrous Gel for Pachyonychia Congenita has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita

Drugs mentioned

• QTORIN 3.9% Rapamycin Anhydrous Gel (Rapamycin)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Pachyonychia Congenita | Phase 3 | Status: COMPLETED